{
    "clinical_study": {
        "@rank": "102574", 
        "arm_group": [
            {
                "arm_group_label": "APD421", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of IV APD421"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose of IV placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at\n      moderate-to-high risk of PONV."
        }, 
        "brief_title": "US Phase III Study of APD421 in PONV", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "PONV", 
        "condition_browse": {
            "mesh_term": "Postoperative Nausea and Vomiting"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients \u2265 18 years of age\n\n          -  Patients undergoing elective surgery (open or laparoscopic technique) under general\n             anaesthesia, expected to last at least one hour from induction of anaesthesia to\n             wound closure and expected to require at least one overnight stay in hospital\n\n        Exclusion Criteria:\n\n          -  Patients scheduled for outpatient/day case surgery\n\n          -  Patients scheduled to undergo intra-thoracic, transplant or central nervous system\n             surgery\n\n          -  Patients scheduled to receive only a local anaesthetic/regional neuraxial\n             (intrathecal or epidural) block\n\n          -  Patients who are expected to remain ventilated for a period after surgery\n\n          -  Patients who are expected to need a naso- or orogastric tube in situ after surgery is\n             completed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "340", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991860", 
            "org_study_id": "DP10015"
        }, 
        "intervention": [
            {
                "arm_group_label": "APD421", 
                "intervention_name": "APD421", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pamidronate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 18, 2013", 
        "location": {
            "contact": {
                "last_name": "Tong J Gan"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina"
                }, 
                "name": "Duke"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting", 
        "overall_contact": {
            "email": "gabrielfox@acaciapharma.com", 
            "last_name": "Gabriel Fox, MB BChir"
        }, 
        "overall_official": {
            "affiliation": "Duke University Medical College", 
            "last_name": "Tong J Gan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients with no PONV in the 24-hour period after end of surgery", 
            "measure": "Complete Response (protection from PONV)", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991860"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Acacia Pharma Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Acacia Pharma Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}